Market Research Report
Global Atopic Dermatitis Therapeutic Market - Opportunities Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analytics, Current Market Size and Market Forecast 2018-2028
|Published by||GervanoRA Data Services LLP||Product code||769588|
|Published||Content info||233 Pages
Delivery time: 1-2 business days
|Global Atopic Dermatitis Therapeutic Market - Opportunities Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analytics, Current Market Size and Market Forecast 2018-2028|
|Published: December 18, 2019||Content info: 233 Pages||
GervanoRA's Market Estimation report "Global Atopic Dermatitis Therapeutic Market - Opportunities Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analytics, Current Market Size and Market Forecast 2018-2028" analyzed the current and upcoming opportunities in the Atopic Dermatitis area by assessing the drug market, covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Atopic Dermatitis industry. The report has been divided into segments like Disease Overview, Market Overview, Pipeline Analytics to provide in depth insights about the market dynamics and ongoing R&D in the Atopic Dermatitis area. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Molecules by Geography, Pipeline Molecules by Drug Class, Pipeline Molecules by Mechanism of Action and Pipeline Molecules by Stage of development. The report evaluated the current market scenario by estimating the market value with respect to Atopic Dermatitis Drug Class, Route of Administration and Age Group. Report primarily focuses on the patent analysis of the key marketed and pipeline drugs to provide a brief understanding about the market opportunities in the Atopic Dermatitis competitive environment. We have also prognosticated the Atopic Dermatitis market share in 11 Major Markets to aid our clients with the commercial and economic opportunities in these geographies.
Our comprehensive analysis on the AD drug pipeline identified 133 drug candidates undergoing different stages of development- from Early R&D to Pre-registration stage. Among these, fifteen drug candidates are in the Phase 3 stage of development, a majority i.e. 46 candidates are in Phase 2 stage, twenty drug candidates are in Phase 1 stage of development and a total of 51 molecules are in non clinical stage of development. We have also identified fourteen drug molecules that are inactive with no drug updates from the year 2015 or have been discontinued. Among them four have been discontinued from further development for AD.
The report has covered more than 110 companies worldwide, involved in the development of new therapeutics for treatment of AD. Growth opportunities in the report have been provided by performing a competitive and comparative analysis on the top 15 Emerging companies in the domain and hence deriving the key leader.
Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on: